Platelet transcriptome in uncontrolled type 2 diabetes mellitus
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB18466 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR1769021_1.fastq.gz | Fastqsanger.gz | |||
| ERR1769021_2.fastq.gz | Fastqsanger.gz | |||
| ERR1769022_1.fastq.gz | Fastqsanger.gz | |||
| ERR1769022_2.fastq.gz | Fastqsanger.gz | |||
| ERR1769023_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 42 |
Similar Datasets
Project description:Results Platelets in non-diabetic patients demonstrated miRNA expression profiles comparable to previously published data. The miRNA expression profiles of platelets in diabetics were similar. Statistical analysis unveiled only three miRNAs (miR-377-5p, miR-628-3p, miR-3137) with high reselection probabilities in resampling techniques, corresponding to signatures with only modest discriminatory performance. Functional annotation of predicted targets for these miRNAs pointed towards an influence of diabetes mellitus on mRNA processing. Conclusions/interpretation We did not find any major differences in platelet miRNA profiles between diabetics and non-diabetics. Minor differences pertained to miRNAs associated with mRNA processing. Thus, previously described differences in plasma miRNAs between diabetic and nondiabetic patients cannot be explained by plain changes in the platelet miRNA profile. Platelet miRNA profiles were assessed in clinically stable diabetic and nondiabetic patients (each n=30). Platelet miRNA was isolated from leucocyte-depleted platelet-rich plasma, and miRNA profiling was performed using LNA micro-array technology (miRBase 18.0, containing 1,917 human miRNAs). Effects of diabetes mellitus were explored by univariate statistical tests for each miRNA, adjusted for potential confounders, and by developing a multivariable signature, which was evaluated by resampling techniques. Platelet phenotype was assessed by light transmission aggregometry and impedance aggregometry.
2014-03-14 | E-GEOD-44093 | biostudies-arrayexpress
Project description:Results Platelets in non-diabetic patients demonstrated miRNA expression profiles comparable to previously published data. The miRNA expression profiles of platelets in diabetics were similar. Statistical analysis unveiled only three miRNAs (miR-377-5p, miR-628-3p, miR-3137) with high reselection probabilities in resampling techniques, corresponding to signatures with only modest discriminatory performance. Functional annotation of predicted targets for these miRNAs pointed towards an influence of diabetes mellitus on mRNA processing. Conclusions/interpretation We did not find any major differences in platelet miRNA profiles between diabetics and non-diabetics. Minor differences pertained to miRNAs associated with mRNA processing. Thus, previously described differences in plasma miRNAs between diabetic and nondiabetic patients cannot be explained by plain changes in the platelet miRNA profile.
2014-03-14 | GSE44093 | GEO
Project description:Diabetes Mellitus Type 1 miRnome
| PRJEB51173 | ENA
Project description:This SuperSeries is composed of the following subset Series: GSE21321: Blood microRNA profiles and upregulation of hsa-miR-144 in males with type 2 diabetes mellitus. GSE26167: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in Type 2 Diabetes mellitus Refer to individual Series
2010-12-18 | E-GEOD-26168 | biostudies-arrayexpress
Project description:Platelet hyperactivity contributes to increased cardiovascular thrombosis in diabetes. Intracellular and released proteins control platelet activity however there are limited proteomic studies of the diabetic platelet. We isolated platelets from 34 patients without, and 42 patients with type 2 diabetes, matched by age, sex, and coronary artery disease burden. Using high sensitivity unbiased proteomics, we measured over 2,400 intracellular proteins, and detected >70 released proteins only secreted by diabetic platelets indicative of hyperactivation. Importantly, we uniquely identified endoplasmic reticulum (ER) protein SEC61B increased in hyperglycemic human and mouse platelets. SEC61B was increased in megakaryocytes in mouse models of diabetes with evidence of associated ER stress. SEC61 is known to act as a channel for calcium leak, a key aspect in platelet hyperactivation. We demonstrate that cultured cells overexpressing SEC61B had increased cytoplasmic calcium flux and decreased protein synthesis. In accordance, hyperglycemic mouse platelets mobilized more cytoplasmic calcium and had lower protein synthesis compared with normoglycemic platelets. Independent induction of ER stress increased platelet SEC61B expression and P-selectin mobilization. We propose a mechanism whereby ER stress-induced upregulation of platelet SEC61B leads to increased cytoplasmic calcium, potentially contributing to platelet hyperactivity in diabetes.
2025-04-19 | PXD049321 | Pride
Project description:Diabetes mellitus (DM) after transplantation remains a crucial clinical problem in kidney transplantation. To obtain insights into molecular mechanisms underlying the development of post-transplant diabetes mellitus (PTDM) and its early impact on glomerular structures, here we comparatively analyze the proteome of histologically normal appearing glomeruli from patients with PTDM from normoglycemic (NG) transplant recipients, and from recipients with pre-existing type 2 DM (PTDM)
2023-10-24 | PXD042188 | Pride
Project description:To evaluate whether serum micoRNAs can be biomarkers for diagnosis of type 1 diabetes mellitus, we analyzed the serum microRNA expression profiles in 6 patients with new-onset type 1 diabetes mellitus and 6 age- and gender-matched healthy controls. A difference was observed in 31 miRNAs between the patients and controls (fold change ≥ 2, P < 0.05)
2017-02-09 | GSE94649 | GEO
Project description:DNA methylation and gestational diabetes mellitus
| PRJEB66494 | ENA
Project description:Type 2 diabetes mellitus represents a major health problem with increasing prevalence worldwide. Limited efficacy of current therapies have prompted a search for novel therapeutic options. Here we show that treatment of pre-diabetic mice with mitochondrially targeted tamoxifen, a potential anti-cancer agent with senolytic activity, improves glucose tolerance and reduces body weight with most pronounced reduction of visceral adipose tissue due to reduced food intake, suppressed adipogenesis and elimination of senescent cells. Glucose-lowering effect of mitochondrially targeted tamoxifen is linked to improvement of type 2 diabetes mellitus-related hormones profile and is accompanied by reduced lipid accumulation in liver. Lower senescent cell burden in various tissues, as well as its inhibitory effect on pre-adipocyte differentiation, results in lower level of circulating inflammatory mediators that typically enhance metabolic dysfunction. Targeting senescence with mitochodrially targeted tamoxifen thus represents an approach to the treatment of type 2 diabetes mellitus and its related comorbidities, promising a complex impact on senescence-related pathologies in aging population of patients with type 2 diabetes mellitus with potential translation into the clinic.
2022-05-20 | PXD031710 | Pride
Project description:tsRNA profiles of gestational diabetes mellitus and healthy control groups were generated by deep sequencing using Illumina NextSeq 500.
2024-05-12 | GSE267259 | GEO